{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.396","value":"21.71"},{"groupId":"OG001","spread":"6.884","value":"18.71"}]}]}],"denomUnitsSelected":"MR images/scans","denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"58"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"193"},{"groupId":"OG001","value":"193"}],"units":"MR images/scans"}],"description":"We analyzed 193 sets of post-gadoteriol and 24 hours post-ferumoxytol T1 weighted scans from 58 patient with high grade glioma. Enhancement volumes normalized to normal appearing white matter were calculated with histogram analysis. Enhancement cube root volumes were compared between the two contrast agents. Ferumoxytol and gadolinium enhanced MR images were obtained from each participant.","dispersionType":"Standard Deviation","groups":[{"description":"Study patients: adult patients with high grade primary malignant brain tumors or with known or suspected brain metastases from histologically confirmed primary cancer\n\nStudy procedures: patients will receive IV ferumoxytol (maximum dose 4 mg/kg, over at least 15 minutes) beginning approximately 15 seconds after start of 3T DSC-MRI and GBCA IV approximately 1 minute and 50 seconds after start of 3T DCE-MRI on day 1. Patients will also undergo MRI without contrast at baseline (before and on day 2. Imaging with ferumoxytol, GBCA and without contrast repeats every 3 weeks for a total of 6 more imaging sessions over up to 5 years.\n\n3 Tesla Magnetic Resonance Imaging: Undergo 3T MRI\n\nDynamic Contrast-Enhanced Magnetic Resonance Imaging: Undergo 3T DCE-MRI\n\nDynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging: Undergo 3T DSC-MRI\n\nFerumoxytol: Given IV\n\nGadolinium: Given IV\n\nMRI-Based Angiogram: Undergo MRA","id":"OG000","title":"Malignant Brain Tumor Patients Undergoing Brain MRI- Gadolinium-enhanced MRI"},{"description":"Study patients: adult patients with high grade primary malignant brain tumors or with known or suspected brain metastases from histologically confirmed primary cancer\n\nStudy procedures: patients will receive IV ferumoxytol (maximum dose 4 mg/kg, over at least 15 minutes) beginning approximately 15 seconds after start of 3T DSC-MRI and GBCA IV approximately 1 minute and 50 seconds after start of 3T DCE-MRI on day 1. Patients will also undergo MRI without contrast at baseline (before and on day 2. Imaging with ferumoxytol, GBCA and without contrast repeats every 3 weeks for a total of 6 more imaging sessions over up to 5 years.\n\n3 Tesla Magnetic Resonance Imaging: Undergo 3T MRI\n\nDynamic Contrast-Enhanced Magnetic Resonance Imaging: Undergo 3T DCE-MRI\n\nDynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging: Undergo 3T DSC-MRI\n\nFerumoxytol: Given IV\n\nGadolinium: Given IV\n\nMRI-Based Angiogram: Undergo MRA","id":"OG001","title":"Malignant Brain Tumor Patients Undergoing Brain- Ferumoxytol-enhanced MRI"}],"paramType":"MEAN","populationDescription":"58 participants had both appropriate ferumoxytol and gadolinium scans available for analysis for this outcome.","reportingStatus":"POSTED","timeFrame":"Summarized after completion of up to 6 imaging sessions (up to 5 years)","title":"Compare Number and Size of Tumors Imaged With Ferumoxytol and Gadolinium Based Contrast Agents (Cube Root Volume)","type":"SECONDARY","typeUnitsAnalyzed":"MR images/scans","unitOfMeasure":"mm"}